Form 4 Filing for Beam Therapeutics Inc.

On October 15 and 16, 2026, John M. Evans, CEO of Beam Therapeutics Inc. (BEAM), executed a series of transactions involving the company's common stock. Evans exercised stock options to acquire 50,000 shares at a price of $1.03 per share, totaling $51,500. Concurrently, he sold 50,000 shares of common stock. The sales occurred at a weighted average price of $23.57 on October 15 and $23.98 on October 16. These transactions were conducted under a Rule 10b5-1 trading plan. Following these transactions, Evans directly holds 1,047,205 shares. Additionally, 103,000 shares are held indirectly through the John M. Evans, III 2018 Irrevocable Trust. The filing also notes the details of stock options granted to Evans, including vesting schedules.